David Berz
Impact in
- Hematology top 5%
- Hematopoietic Stem Cell Transplantation
- Cancer Research top 10%
- MicroRNA in disease regulation
Papers in
- Oncology 49
- HER2/EGFR in Cancer Research 14
- Cancer Immunotherapy and Biomarkers 10
- Colorectal Cancer Treatments and Studies 6
- CAR-T cell therapy research 6
- Lung Cancer Research Studies 6
-
- Lung Cancer Treatments and Mutations 23
- Co-authors
- Gerald A. Colvin (13 shared papers)Peter J. Quesenberry (7 shared papers)Eric S. Winer (5 shared papers)Elise McCormack (4 shared papers)Mark S. Dooner (4 shared papers)Harold J. Wanebo (3 shared papers)Douglas C. Hixson (2 shared papers)Bharat Ramratnam (2 shared papers)
- Journals
- Journal of Clinical Oncology (19 papers)Annals of Oncology (8 papers)Journal of Thoracic Oncology (5 papers)Blood (3 papers)ESMO Open (2 papers)
- Partner nations
- United StatesGermanyJapan
In The Last Decade
David Berz
69 papers receiving 899 citations
Peers
Comparison fields: 5 of 98
- Hematology 157
- Cancer Research 182
- Genetics 127
- Oncology 269
- Immunology 147
Countries citing papers authored by David Berz
This map shows the geographic impact of David Berz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Berz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Berz more than expected).
Fields of papers citing papers by David Berz
This network shows the impact of papers produced by David Berz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Berz. The network helps show where David Berz may publish in the future.
Co-authors
The 25 scholars most cited alongside David Berz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 75 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 179 | |
| 2 | 2010 | 173 | |
| 3 | 2009 | 56 | |
| 4 | 2008 | 43 | |
| 5 | 2020 | 36 | |
| 6 | 2023 | 28 | |
| 7 | 2011 | 25 | |
| 8 | 2018 | 23 | |
| 9 | 2013 | 21 | |
| 10 | 2017 | 21 | |
| 11 | 2011 | 20 | |
| 12 | 2023 | 20 | |
| 13 | 2013 | 20 | |
| 14 | 2011 | 19 | |
| 15 | 2015 | 16 | |
| 16 | 2021 | 15 | |
| 17 | 2008 | 15 | |
| 18 | 2022 | 13 | |
| 19 | 2013 | 13 | |
| 20 | 2009 | 12 |
About David Berz
David Berz is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Hematology and Cancer Research, having authored 75 papers that have together received 932 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (23 papers), HER2/EGFR in Cancer Research (14 papers), Cancer Immunotherapy and Biomarkers (10 papers), Cancer Genomics and Diagnostics (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Colorectal Cancer Treatments and Studies (6 papers), CAR-T cell therapy research (6 papers) and Lung Cancer Research Studies (6 papers). The work is most often cited by research in Hematology (157 citations), Cancer Research (182 citations), Genetics (127 citations), Oncology (269 citations) and Immunology (147 citations). David Berz has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include Gerald A. Colvin, Peter J. Quesenberry, Eric S. Winer, Elise McCormack, Mark S. Dooner, Harold J. Wanebo, Douglas C. Hixson, Bharat Ramratnam, Jason M. Aliotta and Mandy Pereira. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Blood and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.